TVTX

Travere Therapeutics, Inc. Common Stock

34.58

USD

TVTX Earnings Reports

Positive Surprise Ratio

TVTX beat 16 of 40 last estimates.

40%

Next Report

Date of Next Report

Feb 18, 2026

Estimate for Q4 25 (Revenue/ EPS)

$145.08M

-$0.12

Implied change from Q3 25 (Revenue/ EPS)

-12.00%

-142.86%

Implied change from Q4 24 (Revenue/ EPS)

+93.99%

-83.56%

Travere Therapeutics, Inc. Common Stock earnings per share and revenue

On Oct 30, 2025, TVTX reported earnings of 0.28 USD per share (EPS) for Q3 25, beating the estimate of -0.21 USD, resulting in a 232.08% surprise. Revenue reached 164.86 million, compared to an expected 108.66 million, with a 51.71% difference. The market reacted with a +18.58% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 16 analysts forecast an EPS of -0.12 USD, with revenue projected to reach 145.08 million USD, implying an decrease of -142.86% EPS, and decrease of -12.00% in Revenue from the last quarter.

FAQ

What were Travere Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Travere Therapeutics, Inc. Common Stock reported EPS of $0.28, beating estimates by 232.08%, and revenue of $164.86M, 51.71% above expectations.

How did the market react to Travere Therapeutics, Inc. Common Stock's Q3 2025 earnings?

The stock price moved up 18.58%, changed from $29.65 before the earnings release to $35.16 the day after.

When is Travere Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Feb 18, 2026.

What are the forecasts for Travere Therapeutics, Inc. Common Stock's next earnings report?

Based on 16 analysts, Travere Therapeutics, Inc. Common Stock is expected to report EPS of -$0.12 and revenue of $145.08M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.